docetaxel anhydrous has been researched along with Carcinoma, Anaplastic in 208 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (4.81) | 18.2507 |
| 2000's | 65 (31.25) | 29.6817 |
| 2010's | 118 (56.73) | 24.3611 |
| 2020's | 15 (7.21) | 2.80 |
| Authors | Studies |
|---|---|
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Fukugawa, Y; Matsuyama, T; Murakami, D; Nishimoto, K; Orita, Y; Oya, N; Saito, T; Toya, R; Watakabe, T | 1 |
| Driessen, CML; Lassche, G; Uijen, MJM; van Engen-van Grunsven, ACH; van Herpen, CML | 1 |
| Mahmoudi, A; Malaekeh-Nikouei, B; Moosavian, SA; Shakib, Z | 1 |
| Amsberg, GV; Böhmer, D; Krabbe, LM; Krause, BJ; Merseburger, AS; Perner, S | 1 |
| Guo, Z; Hu, X; Liu, Z; Lv, R; Meng, L; Yan, L; Zhang, Y | 1 |
| Huang, J; Ji, X; Jing, X; Liu, Y; Yang, S; Yun, Y | 1 |
| Liang, Q; Liu, Y; Thakur, A; Xu, Z; Yan, Y; Zeng, S; Zhou, S | 1 |
| El-Naggar, A; Ferrarotto, R; Wotman, M | 1 |
| Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V | 1 |
| Kanao, H; Koike, R; Kurihara, N; Nomura, H; Omatsu, K; Sekizawa, A; Yunokawa, M | 1 |
| Albuquerque, L; Guerreiro, C; Reimão, S | 1 |
| Akashi, H; Ando, K; Furuya, D; Kawada, H; Kawai, H; Ogawa, Y; Suzuki, R | 1 |
| Asemota, H; Barker, J; Delgoda, R; Erhabor, J; Foster, K; Kendal-Smith, A; Langat, MK; Matsabisa, M; Oyenihi, O; Rademan, S | 1 |
| Duran, GE; Francisco, EB; Moisan, F; Sikic, BI; Wang, YC | 1 |
| Hamauchi, S; Iida, Y; Kamijo, T; Kawahira, M; Nishimura, T; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Yasui, H; Yokota, T | 1 |
| Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakatani, M; Obayashi, C; Sho, M; Takano, M; Wakatsuki, K | 1 |
| Chen, L; Guo, R; Li, WF; Lin, AH; Liu, X; Ma, J; Mao, YP; Sun, Y; Tang, LL; Xu, C; Yang, SP; Zhang, Y; Zhou, GQ | 1 |
| Bernard-Marty, C; Dalenc, F; de Lafontan, B; Dulguerova, P; Guerrero, D; Guyonnaud, J; Levasseur, N; Levecq, JM; Massabeau, C; Ranc Royo, AL; Ribet, V; Rossi, AB; Salas, S; Sarda, C; Sibaud, V | 1 |
| Amoura, Z; Barbaud, A; Francès, C; Mathian, A; Monfort, JB; Senet, P | 1 |
| Hou, X; Jiang, G; Liu, T; Wang, Y; Wu, T; Wu, X; Xie, H; Xie, M | 1 |
| He, X; Hu, C; Xue, F | 1 |
| Chen, J; Chen, QQ; Liu, X; Peng, XH; Peng, XY; Qi, J; Tan, JJ; Wang, F; Yu, B; Zeng, FF | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| Doi, T; Okino, T; Sakamoto, T | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Liu, L; Ma, C; Tang, H; Xiong, W; Zhao, Y | 1 |
| Kwong, B; Tabata, MM | 1 |
| Aoki, D; Iwamori, M; Kiguchi, K; Mikami, M; Tanaka, K | 1 |
| Hanai, N; Harata, I; Hasegawa, Y; Hirakawa, H; Miyazaki, T; Okamoto, H; Ozawa, T; Suzuki, A | 1 |
| Chen, G; Dai, J; Wang, XY; Xie, CH; Zeng, L; Zhong, YH; Zhou, YF | 1 |
| Henry-Tillman, RS; Hutchins, LF; Klimberg, VS; Korourian, S; Makhoul, I; Siegel, ER; Westbrook, KC | 1 |
| Chen, JP; Chen, XL; Chen, XZ; Chen, ZX; Hu, JK; Li, H; Li, K; Liao, YB; Wang, L; Yang, C; Yang, K; Zhang, B; Zhou, ZG | 1 |
| Demirkilic, U; Doganci, S; Erol, G; Gunay, C; Kadan, M; Kaya, E | 1 |
| Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW | 1 |
| Gu, K; Hu, QC; Wang, JP; Wu, YW; Zhai, XM; Zhang, JN | 1 |
| Hai, T; Kang, H; Rong, G; Sun, H; Wang, Y | 1 |
| Bassini, A; Bertola, M; Del Conte, A; Foltran, L; Gion, M; Lorenzon, M; Micheli, E; Saracchini, S; Sulfaro, S; Tuccia, F; Tumolo, S | 1 |
| Chen, X; Chew, SC; Chowbay, B; Lee, EJ; Lim, J; Singh, O; Tan, EH | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX | 1 |
| Guo, CY; Han, SH; Song, HP; Yu, L; Zhang, PJ; Zhang, Z | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Liu, S; Nielsen, DL; Nielsen, TO; Wallden, B | 1 |
| Chen, J; Du, C; Hu, C; Jiang, J; Liu, C; Wang, X; Ying, H; Zhou, J | 1 |
| Bortolus, R; Garbeglio, A; Ghadjar, P; Giannarini, G; Gnech, M; Guttilla, A; Palumbo, V; Valent, F; Zattoni, F | 1 |
| Barone, M; Basilico, R; Carella, C; Colasante, A; De Tursi, M; Filippone, A; Guetti, L; Mani, A; Massari, R | 1 |
| Huang, SM; Li, JX; Lu, TX; Wen, BX | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Abe, H; Kondo, Y; Miura, T; Nemoto, K; Nomura, S; Shioji, G; Tsuboi, N | 1 |
| Charehbili, A; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Smit, VT; van de Velde, CJ; van Leeuwen-Stok, AE; Wasser, MN | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Chen, LK; Hu, ZH; Huang, Y; Liu, JL; Ma, Y; Ma, YX; Wei, CL; Wu, X; Xu, F; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY; Zou, BY | 1 |
| Cheng, PJ; Li, P; Shan, GP; Zhang, L | 1 |
| Chen, L; Ding, B; Gao, J; Han, Y; Jin, G; Liu, C; Liu, X; Ma, G; Tian, X; Xuan, S | 1 |
| Rexer, H | 1 |
| Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A | 1 |
| Alvarez, E; Campos Balea, B; Casal, J; Castellanos, J; Fernández, A; Gallardo, E; González, P; Grande, C; Jorge, M; López, C; López, R; Quintero-Aldana, G; Salgado, M; Varela, S; Villanueva, MJ | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G | 1 |
| Li, J; Liang, H; Pan, F; Pang, X; Ruan, Z; Zhang, Y; Zou, L | 1 |
| Du, N; Kang, HR; Li, XS; Ma, J; Yao, FF; Yao, S | 1 |
| Chen, L; Guo, R; Li, WF; Lin, AH; Liu, X; Ma, J; Sun, Y; Zhang, F; Zhang, Y | 1 |
| Arai, Y; Komatsu, M; Nishimura, G; Oridate, N; Sakuma, Y; Sano, D; Shiono, O; Taguchi, T; Takahashi, M; Yabuki, K | 1 |
| Casanova, M; Errihani, H; Ferrari, A; Grzegorzewski, KJ; Orbach, D; Özyar, E; Pan, J; Patte, C; Shen, L; Varan, A; Veyrat-Follet, C; Zhang, L | 1 |
| Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH | 1 |
| Bi, T; Gong, X; He, Q; Jin, F; Li, Y; Li, Z; Long, J; Luo, X; Qu, B; Wu, W | 1 |
| Clauditz, T; Knecht, R; Laban, S; Muenscher, A; Schafhausen, P; Tribius, S; Veldhoen, S; Zielinski, V | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Bonanno, L; Caminiti, F; Cammaroto, G; De Salvo, S; Galletti, B; Galletti, F; Mannella, VK; Santoro, R | 1 |
| Du, L; Ma, L; Wang, Q; Yang, S; Zhang, X; Zhao, F | 1 |
| Chen, J; Lin, S; Yang, S; Zhang, S | 1 |
| Huang, CQ; Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yang, XJ; Zhang, Q | 2 |
| Jiang, G; Liu, F; Liu, T; Wang, W; Wang, Y; Wu, T; Wu, X; Xie, M; Zhang, T | 1 |
| Amin, AL; Barnadas, A; Bretel Morales, D; Connor, CS; Cortes, J; Del Monte-Millán, M; Fabian, CJ; Fuentes Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; Gonzalez-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; López-Tarruella, S; Mammen, JM; Márquez-Rodas, I; Martin, M; Massarrah, T; McGinness, MK; Moreno, F; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Ward, C | 1 |
| Ai, P; Gong, FM; Hu, X; Peng, X; Ren, M; Tang, J; Wu, S | 1 |
| Fujiwara, K; Kigawa, J; Nagao, S; Nishimura, R; Shimada, M; Shoji, T; Sugiyama, T; Takeshima, N; Takizawa, K; Yamaguchi, S | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Flaig, TW; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Bei, JX; Cao, KJ; Chen, MY; Chen, QY; Guo, L; Guo, SS; Guo, X; Hong, MH; Liu, LT; Liu, XW; Ma, J; Mai, HQ; Mo, HY; Qian, CN; Shao, JY; Sun, Y; Tang, LQ; Xie, CM; Zeng, MS; Zhang, L; Zhao, C | 1 |
| Ai, J; Hou, M; Li, W; Liu, H; Tan, G; Xie, Z; Zeng, R | 1 |
| An, X; Cao, Y; Chen, T; Deng, Y; Han, H; Shi, Y; Teng, X; Xue, C; Yang, W; Zhou, F | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Cavallo, A; Cova, A; Granata, R; Huber, V; Iacovelli, NA; Imbimbo, M; Licitra, L; Locati, L; Mariani, L; Miceli, R; Orlandi, E; Resteghini, C; Rivoltini, L | 1 |
| Afors, K; Akladios, C; Baldauf, JJ; Hummel, M; Kurtz, JE; Lecointre, L; Marchal, F; Mathelin, C; Petit, T; Rebstock, LE; Schrot-Sanyan, S | 1 |
| Blanchard, P; De Felice, F; Deutsch, E; El Khoury, C; Even, C; Gorphe, P; Janot, F; Levy, A; Nguyen, F; Ou, D; Tao, Y; Temam, S | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Armstrong, AJ; Bono, J; Dmuchowski, C; Fizazi, K; Forer, D; Hirmand, M; Saad, F; Scher, HI; Shore, ND | 1 |
| Chen, L; Ma, J; Mao, YP; Sun, Y; Tang, LL; Yao, JJ; Yu, XL; Zhang, F; Zhang, WJ; Zhou, GQ | 1 |
| Bamias, A; Briasoulis, E; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karina, M; Koutras, A; Pavlidis, N; Pentheroudakis, G; Samantas, E; Samelis, G; Xiros, N | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Calvo, L; Cruz, JJ; García-Mata, J; García-Palomo, A; Mel, R; Ramos, M | 1 |
| Guntinas-Lichius, O; Klussmann, JP; Rühlow, S; Veelken, F | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Hasegawa, S; Kimura, S; Maekawa, T; Matsumoto, S; Sato, K; Tanaka, F; Wada, H | 1 |
| BalmerMajno, S; Bodis, S; Borner, M; Hess, V; Köberle, D; Mingrone, W; Pestalozzi, BC; Popescu, R; Roth, A; Ruhstaller, T; Schnider, A; Schuller, JC; Terraciano, L; von Moos, R; Widmer, L | 1 |
| Ajarim, DS; Al-Malik, OA; Al-Tweigeri, TA; Alsayed, AA; Alshabanah, MO; El-Husseiny, GA; Elkum, NB; Ezzat, AA; Fatani, DM; Rahal, MM; Tulbah, AM | 1 |
| Hu, WH; Li, JS; Peng, M; Qi, SN; Xie, FY; Zou, GR | 1 |
| Harshman, LC; Srinivas, S | 1 |
| Habuchi, T; Numakura, K; Takahashi, N; Tsuchiya, N | 1 |
| Abe, M; Doiguchi, M; Hasuo, T; Miyamoto, Y; Sakamoto, F; Tanigawa, T | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Abrial, C; Barthomeuf, C; Bayet-Robert, M; Chollet, P; Durando, X; Gachon, F; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Planchat, E | 1 |
| Arellano, J; Asukai, Y; Camps, C; Cassinello, A; Dilla, T; Sacristán, JA; Taipale, K; Valladares, A; Wood, E | 1 |
| Andreoni, B; Biffi, R; Bonomo, G; Chiappa, A; Crosta, C; Fazio, N; Fiori, G; Huber, O; Luca, F; Orsi, F; Roth, A; Schuller, JC; Zampino, MG | 1 |
| Ando, Y; Arima, H; Fujimoto, Y; Imai, T; Inada, M; Kamei, S; Kawada, K; Kikumori, T; Kitagawa, K; Mitsuma, A; Sawaki, M | 1 |
| Agatsuma, T; Ichiyama, T; Koizumi, T; Kubo, K; Tanabe, T; Yamamoto, H | 1 |
| Bruzzone, A; Dellepiane, M; Figliomeni, M; Ghio, R; Grillo-Ruggieri, F; Grimaldi, A; Mencoboni, M; Moratti, G; Rebella, L; Salami, A; Scasso, F; Spigno, F | 1 |
| Kasman, I; Plowman, GD; Roy Choudhury, K | 1 |
| Dieckmann, K; Hoffmann, M; Koperek, O; Niederle, B; Raderer, M; Scheuba, C; Troch, M | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Ang, MK; Chowbay, B; Gao, F; Leong, SS; Lim, WT; Ngeow, J; Tan, EH; Toh, CK | 1 |
| Jeong, JH; Jung, SY; Kang, HS; Kim, EA; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Feng, N; Hua, L; Li, P; Niu, X; Tao, J; Wang, X; Wang, Z; Wu, D; Wu, H; Xu, B; Zhang, W; Zhang, X | 1 |
| Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R | 1 |
| Chilimoniuk, M; Maksimowicz, T; Olszewska, E | 1 |
| Baker, JH; Brooks, DE; Burt, HM; Gleave, ME; Liggins, R; Manisali, I; Matsui, Y; Minchinton, AI; Mugabe, C; So, AI | 1 |
| Fujiwara, K; Kigawa, J; Kitada, F; Nagao, S; Nishimura, R; Takekida, S; Terakawa, N; Yamaguchi, S; Yoshida, N | 1 |
| Huang, Q; Li, DJ; Lu, MQ; Ren, JH; Su, J; Wu, YP; Xu, XH; Xue, F; Yi, F | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Hedman, H; Henriksson, R; Hesselius, P; Lennartsson, J; Wu, X | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Dai, Y; Fan, CY; Neis, JP; Spring, PM; Vural, E; Xie, CH | 1 |
| Bontenbal, M; Bos, MM; Braun, HJ; Creemers, GJ; Erdkamp, FL; Hamberg, P; Klijn, JG; Loosveld, OJ; Muller, EW; Portielje, JE; Pruijt, JF; Schmitz, PI; Seynaeve, C; Smit, WM; Stouthard, JM; van Deijk, GA; van der Stelt-Frissen, IN | 1 |
| Kim, DN; Lee, SK; Shin, HJ | 1 |
| Bang, YJ; Han, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, JH; Kim, TY; Lee, SH; Nam, BH; Noh, DY; Oh, DY; Park, IA; Park, S | 1 |
| Benlloch, S; Chen, H; Costa, C; Ding, Y; Gimenez-Capitan, A; Liu, B; Meng, F; Moran, T; Qian, X; Rosell, R; Sanchez, JJ; Taron, M; Wei, J; Yu, L; Zou, Z | 1 |
| Armaiz-Pena, G; Baggerly, KA; Bottsford-Miller, J; Coleman, RL; Deavers, MT; Graybill, WS; Kim, HS; Kim, SM; Landen, CN; Lee, JS; Lopez-Berestein, G; Nick, AM; Ozpolat, B; Ram, PT; Sood, AK; Stone, RL; Tekedereli, I; Villares, G; Vivas-Mejia, P | 1 |
| Brandi, M; Colucci, G; Di Benedetto, A; Di Lauro, L; Filippelli, G; Foggi, P; Gebbia, N; Giannarelli, D; Giotta, F; Lopez, M; Massidda, B; Mottolese, M; Schittulli, F; Vici, P | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY | 1 |
| Horita, N; Imai, S; Noma, B; Ono, T; Sasaki, N; Shiota, Y; Tahara, K; Taniguchi, A | 1 |
| Bollag, DT; Caralt, M; Cortés, J; Cortes-Funes, H; Delaloge, S; Miles, DW; Pierga, JY; Pritchard, KI | 1 |
| Hirama, M; Horiuchi, C; Ishitoya, J; Komatsu, M; Matsuda, H; Mori, M; Niho, T; Nishimura, G; Sakuma, Y; Shiono, O; Taguch, T; Takahashi, M; Tsukuda, M | 1 |
| Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J | 1 |
| Cai, XY; Deng, YM; Feng, WN; Huang, ZL; Lin, L; Lu, QX; Wei, WH; Wu, YF; Xu, T; Zhang, GY | 1 |
| Kim, E; Matsuse, M; Mitsutake, N; Ohtsuru, A; Saenko, V; Suzuki, K; Yamashita, S | 1 |
| Aoki, T; Kaneko, A; Ota, Y; Yamazaki, H | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Culliney, B; Harrison, LB; Hauerstock, D; Hu, KS; Jacobson, A; Li, Z; Manolidis, S; Mourad, WF; Persky, M; Schantz, S; Shourbaji, RA; Tran, T; Urken, M | 1 |
| Bridges, AS; Chu, KS; DeSimone, JM; Enlow, EM; Hasan, W; Kuijer, JL; Luft, JC; Napier, ME; Rawal, S; Walsh, MD; Zamboni, WC | 1 |
| Fietkau, R; Iro, H; Kuwert, T; Lell, M; Lettmaier, S; Schmidt, D; Semrau, S; Waldfahrer, F | 1 |
| Ajani, JA | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Bast, RC; Berek, JS; Bookman, MA; Cannistra, SA; Crum, CP; DePriest, PD; Garber, JE; King, L; Koh, WJ; Markman, M; McGuire, WP; Rose, PG; Rowinsky, EK; Rustin, GJ; Skates, SJ; Vasey, PA | 1 |
| Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H | 1 |
| Brumfield, B; Clayman, G; Diaz, EM; Garden, A; Glisson, BS; Johnson, FM; Khuri, FR; Kies, M; Morrison, W; Palmer, JL; Papadimitrakopoulou, V | 1 |
| Becht, C; Culine, S; Cupissol, D; Fabbro, M; Pinguet, F; Pouessel, D; Romieu, G; Ychou, M | 1 |
| Borner, MM; de Braud, F; Fazio, N; Goldhirsch, A; Herrmann, R; Maibach, R; Morant, R; Roth, AD; Sessa, C; Stupp, R | 1 |
| Aviles, V; Benson, AB; Berlin, JD; Harris, JE; Levy, DE; Shepard, RC; Stuart, K; Thomas, JP | 1 |
| Broglio, KR; Buzdar, AU; Esteva, FJ; Gonzalez-Angulo, AM; Hortobagyi, GN; Krishnamurthy, S; Pusztai, L; Yamamura, Y | 1 |
| Barceló, JR; López-Vivanco, G; Muñoz, A | 1 |
| Sulkes, A | 1 |
| Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV | 1 |
| Misawa, H; Ochiai, K; Tanaka, T; Yasuda, M | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Alvero, AB; Chen, W; Dwipoyono, B; Garg, M; Hao, XY; Kamsteeg, M; Mor, G; O'Malley, D; Rutherford, T; Sapi, E | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Iba, T; Kanamori, Y; Kigawa, J; Oishi, T; Shimada, M; Terakawa, N; Watanabe, A | 1 |
| Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Hwangbo, B; Kim, CG; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Park, SR; Ryu, KW | 1 |
| Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohno, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB | 1 |
| Douek, M; Tobias, J | 1 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Fahlke, J; Florschuetz, A; Greiner, C; Hahnfeld, S; Hribaschek, A; Kettner, E; Klein, H; Kuhn, R; Lippert, H; Manger, T; Meyer, F; Ridwelski, K; Wilhelm, G | 1 |
| Endo, Y; Fujiwara, T; Hioki, M; Ikeda, Y; Kagawa, S; Kishimoto, H; Sakai, R; Tanaka, N; Urata, Y | 1 |
| Aramendía, JM; Fernández-Hidalgo, O; García-Manero, M; López, G; Nieto, Y; Santisteban, M | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| Burla, ML; Dauphine, CE; Gonzalez, KD; Isaac, NM; Kaufmann, P; Rosing, D; Vargas, HI; Vargas, MP | 1 |
| Hernández-Vargas, H; Moreno-Bueno, G; Palacios, J | 2 |
| Ember, A; Esik, O; Horváth, OP; Kalmár, K; Papp, A; Yousuf, AF | 1 |
| Ege, B; Kurukahvecioglu, O; Poyraz, A; Taneri, F; Tezel, E | 1 |
| Ali-Fehmi, R; Elhammady, E; Jiang, JZ; Malone, JM; Munkarah, AR; Saed, GM | 1 |
| Chang, HM; Jo, JC; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Jeen, YT; Kim, HK; Kim, YH; Seo, HY; Shim, BY; Yang, J | 1 |
| Oriana, S; Orlandi, L; Silvestrini, R; Zaffaroni, N | 1 |
| Bissery, MC; Lavelle, F; Vrignaud, P | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Trudeau, ME | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
| Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vadhan-Raj, S; Valero, V; Vasuratna, A; Verschraegen, CF | 1 |
| Hamaguchi, Y; Hasegawa, S; Hisatomi, H; Ichikawa, Y; Ishikawa, T; Kamiyama, M; Momiyama, N; Narita, T; Shimada, H | 1 |
| Engblom, P; Grènman, S; Kulmala, J; Rantanen, V | 1 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Olszewski, W | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Bevers, M; Freedman, R; Kavanagh, JJ; Kudelka, AP; Moon, C; Verschraegen, CF | 1 |
| Hirabayashi, K; Hoshiai, H; Katsumata, N; Kohno, I; Noda, K; Ogita, S; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
| Bastert, G; Beldermann, F; Geberth, M; Goerner, R; Lenz, F; Schneeweiss, A; Solomayer, E | 1 |
| Hazama, K; Kagisaki, K; Matsuda, H; Miyoshi, S; Ohta, M; Shintani, Y | 1 |
| Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E | 2 |
| Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA | 1 |
15 review(s) available for docetaxel anhydrous and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Humans; Palliative Care; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maxillary Sinus Neoplasms; Neoplasm Invasiveness; Otorhinolaryngologic Surgical Procedures; Taxoids; Tomography, X-Ray Computed | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
[Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].
Topics: Aged; Antineoplastic Agents; Carcinoma; Chromosomes, Human, Pair 11; Combined Modality Therapy; Docetaxel; Humans; Leukemia, Myelomonocytic, Acute; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prostatectomy; Prostatic Neoplasms; Taxoids; Translocation, Genetic | 2009 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Trimodality management of sinonasal undifferentiated carcinoma and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Docetaxel for gastric and esophageal carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
[Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2004 |
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Telling cells how to die: docetaxel therapy in cancer cell lines.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Death; Cell Line, Tumor; Docetaxel; Genes, cdc; Humans; Microtubules; Taxoids | 2007 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion, Malignant; Taxoids; Thymus Neoplasms; Vena Cava, Superior | 2001 |
80 trial(s) available for docetaxel anhydrous and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma.
Topics: Carcinoma; Docetaxel; Fever; Humans; Lung; Lung Neoplasms; Nausea; Proteinuria; Treatment Outcome; Vomiting | 2022 |
Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Docetaxel; Fluorouracil; Humans; Prospective Studies; Stomach Neoplasms | 2023 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Emollients; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hand-Foot Syndrome; Humans; Hydrotherapy; Hyperpigmentation; Lymphedema; Manual Lymphatic Drainage; Massage; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pruritus; Quality of Life; Radiodermatitis; Radiotherapy, Adjuvant; Skin Care; Skin Diseases; Tamoxifen; Taxoids | 2018 |
Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy.
Topics: Adult; Aged; Carcinoma; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Survival Analysis; Taxoids; Treatment Outcome; Tumor Burden; Young Adult | 2018 |
Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Taxoids; Young Adult | 2013 |
Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Female; Humans; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; White People | 2015 |
Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.
Topics: Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Mouth Neoplasms; Nausea; Neoplasm Staging; Taxoids; Treatment Outcome | 2014 |
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma; Constitutive Androstane Receptor; Docetaxel; Female; Haplotypes; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platelet Count; Polymorphism, Single Nucleotide; Receptors, Cytoplasmic and Nuclear; Taxoids | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Herpesvirus 4, Human; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2014 |
[Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2013 |
Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective ph
Topics: Aged; Androgen Antagonists; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Risk; Taxoids | 2014 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Taxoids; Treatment Outcome; Tumor Burden; Zoledronic Acid | 2014 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Radiography; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Prognosis; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome; Young Adult | 2015 |
[Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostat
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma; Castration; Combined Modality Therapy; Dendritic Cells; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Placebo Effect; Prevalence; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2015 |
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Palliative Care; Spain; Stomach Neoplasms; Survival Analysis; Taxoids | 2015 |
Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease-Free Survival; Docetaxel; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids | 2015 |
Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids; Young Adult | 2015 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Child; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Taxoids; Treatment Outcome | 2016 |
Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Drug Design; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult | 2015 |
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Chronotherapy; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nausea; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2015 |
A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Taxoids; Young Adult | 2016 |
An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyclobutanes; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Taxoids | 2016 |
Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cyclobutanes; Cytoreduction Surgical Procedures; Docetaxel; Drug Synergism; Feasibility Studies; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Topics: Antineoplastic Agents; Benzamides; Carcinoma; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Greece; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Outpatients; Palliative Care; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2008 |
Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asthenia; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Eruptions; Female; Granulocyte Colony-Stimulating Factor; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Stomatitis; Taxoids | 2008 |
Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Palliative Care; Quality of Life; Recurrence; Survival Analysis; Taxoids | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy; Taxoids; Treatment Outcome | 2009 |
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Estrogens; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Progesterone; Prospective Studies; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Treatment Outcome; Young Adult | 2010 |
[Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Mucositis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Prospective Studies; Remission Induction; Taxoids; Young Adult | 2009 |
A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome; Urethral Neoplasms | 2009 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Curcumin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Time Factors; Treatment Outcome | 2010 |
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Endosonography; Europe; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Radionuclide Imaging; Stomach Neoplasms; Taxoids; Time Factors; Tomography, Spiral Computed; Treatment Outcome | 2010 |
The feasibility study of docetaxel in patients with anaplastic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Taxoids; Thyroid Neoplasms | 2010 |
Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Palliative Care; Quality of Life; Taxoids; Treatment Failure | 2011 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure | 2011 |
Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast c
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prospective Studies; Survival Analysis; Taxoids | 2012 |
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium | 2012 |
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Comorbidity; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Minor Surgical Procedures; Neoadjuvant Therapy; Neoplasm Metastasis; Placebos; Postoperative Hemorrhage; Taxoids | 2012 |
Trimodality management of sinonasal undifferentiated carcinoma and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.
Topics: Adult; Aged; Carboplatin; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms, Unknown Primary; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2004 |
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Failure; United States | 2004 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prospective Studies; Taxoids | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2005 |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2005 |
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Time Factors | 2005 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Taxoids | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Malignant pleural mesothelioma: a phase II trial with docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids | 2002 |
116 other study(ies) available for docetaxel anhydrous and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation.
Topics: Adult; Aged; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Laryngeal Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Vocal Cords | 2022 |
Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Retrospective Studies; Salivary Ducts; Trastuzumab | 2022 |
PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; CHO Cells; Colonic Neoplasms; Cricetinae; Cricetulus; Docetaxel; Drug Carriers; Drug Delivery Systems; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Polyethylene Glycols | 2022 |
The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2022 |
Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.
Topics: Anilides; Carcinoma; Docetaxel; Humans; Male; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2022 |
The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis.
Topics: Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Docetaxel; Female; Humans; Molecular Docking Simulation; Prognosis; Proteomics; Receptors, Retinoic Acid | 2023 |
Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Docetaxel; ErbB Receptors; Female; Humans; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Salivary Glands; Trastuzumab | 2023 |
Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix.
Topics: Carboplatin; Carcinoma; Cervix Uteri; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Hysterectomy; Lymphatic Metastasis; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2023 |
Radiation recall myelitis following capecitabine: First case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma; Combined Modality Therapy; Docetaxel; Drug Substitution; Female; Humans; Hyperbaric Oxygenation; Letrozole; Middle Aged; Myelitis; Myositis; Prednisolone; Radiodermatitis; Radiotherapy, Adjuvant; Spinal Cord; Spinal Neoplasms; Thoracic Vertebrae | 2020 |
Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Hepatocellular; Docetaxel; Epirubicin; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Treatment Outcome; Tretinoin | 2020 |
Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin.
Topics: Annona; Antineoplastic Agents; Carcinoma; Caspases; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Furans; Humans; Lactones; Male; Membrane Potential, Mitochondrial; Phytotherapy; Plant Bark; Plant Extracts; Plant Leaves; Prostatic Neoplasms; Reactive Oxygen Species | 2020 |
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Topics: Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gene Expression; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Ovarian Neoplasms; Paclitaxel; Polymerization; Taxoids; Tubulin; Tumor Suppressor Protein p53; Vimentin; Vinblastine | 2017 |
Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2017 |
Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.
Topics: Adult; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Prognosis; Survival Analysis; Taxoids; Young Adult | 2018 |
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Radiotherapy, Adjuvant; Raynaud Disease; Remission Induction; RNA Polymerase III; Scleroderma, Systemic; Taxoids; Tonsillectomy; Young Adult | 2018 |
CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo.
Topics: Animals; beta-Cyclodextrins; Carcinoma; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Polylysine; Proliferating Cell Nuclear Antigen; RNA, Small Interfering; Taxoids; Transplantation, Heterologous | 2017 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Disease-Free Survival; Docetaxel; Endostatins; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy; Retrospective Studies; Taxoids | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
[Pulmonary Metastasis of Gastric Cancer as Carcinomatous Lymphangiosis at Five and Half Years after Surgery;Report of a Case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Efficacy of trastuzumab combined with cisplatin and docetaxel on gastric cardia carcinoma and its influence on HER2 and cyclin D1 expressions.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Cisplatin; Cyclin D1; Docetaxel; Humans; Neoplasm Proteins; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
Periorbital dermatitis in patients receiving docetaxel in combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Cisplatin; Docetaxel; Drug Eruptions; Facial Dermatoses; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Nivolumab; Parotid Neoplasms; Skull Base Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2019 |
Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Glycolipids; Humans; Hydrophobic and Hydrophilic Interactions; Ovarian Neoplasms; Paclitaxel | 2019 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pneumonectomy; Prognosis; Retrospective Studies; Taxoids; Thoracotomy | 2013 |
Acute arterial thrombosis following chemotherapy in a patient with a gastric carcinoma.
Topics: Acute Disease; Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoma; Cisplatin; Docetaxel; Fluorouracil; Humans; Male; Popliteal Artery; Risk Factors; Stomach Neoplasms; Taxoids; Thrombectomy; Thrombosis; Treatment Outcome; Ultrasonography, Doppler | 2013 |
Significance of XRCC1 Codon399 polymorphisms in Chinese patients with locally advanced nasopharyngeal carcinoma treated with radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Genotype; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Radiation Tolerance; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2016 |
Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Docetaxel; Drug Resistance, Neoplasm; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Taxoids; Transcriptome; Tumor Microenvironment | 2013 |
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Messenger; Taxoids | 2014 |
Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase (99m)Tc-MIBI SPECT/CT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Radiopharmaceuticals; Taxoids; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Young Adult | 2014 |
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Kaplan-Meier Estimate; Laparotomy; Length of Stay; Middle Aged; Neoadjuvant Therapy; Omentum; Ovarian Neoplasms; Peritoneal Neoplasms; Peritoneum; Polyethylene Glycols; Postoperative Complications; Recurrence; Taxoids; Treatment Outcome | 2014 |
Prognostic factors on overall survival of newly diagnosed metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Carcinoma; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Neck; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Survival Rate; Taxoids; Young Adult | 2014 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
[Marked efficacy of multimodality therapy for ureteral cancer producing granulocyte colony-stmimulating factor].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Taxoids; Ureteral Neoplasms | 2014 |
Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2015 |
Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Case-Control Studies; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Gamma Rays; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Risk; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Olfactory event-related potentials: a new approach for the evaluation of olfaction in nasopharyngeal carcinoma patients treated with chemo-radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Evoked Potentials; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Olfaction Disorders; Radiotherapy, Intensity-Modulated; Smell; Surveys and Questionnaires; Taxoids | 2016 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; China; Cyclobutanes; Cytoreduction Surgical Procedures; Databases, Factual; Docetaxel; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Sample Size; Stomach Neoplasms; Taxoids; Treatment Outcome | 2016 |
Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy.
Topics: Animals; Apoptosis; beta-Cyclodextrins; Carcinoma; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Female; Folic Acid; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Hydrophobic and Hydrophilic Interactions; Magnetic Resonance Spectroscopy; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Polylysine; Proliferating Cell Nuclear Antigen; RNA, Small Interfering; Taxoids; Tissue Distribution; Transfection | 2016 |
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Combined Modality Therapy; Docetaxel; Female; Filgrastim; Genes, BRCA1; Genes, BRCA2; Humans; Kansas; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Observational Studies as Topic; Polyethylene Glycols; Prospective Studies; Spain; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Proteomic analysis of docetaxel resistance in human nasopharyngeal carcinoma cells using the two-dimensional gel electrophoresis method.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Phosphopyruvate Hydratase; Proteomics; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids | 2016 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2017 |
Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Blockage of SSRP1/Ets-1/Pim-3 signalling enhances chemosensitivity of nasopharyngeal carcinoma to docetaxel in vitro.
Topics: Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; High Mobility Group Proteins; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Neoplasm Invasiveness; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Signal Transduction; Taxoids; Transcriptional Elongation Factors | 2016 |
Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cytokines; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Interleukin-1beta; Interleukin-6; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal Neoplasms; Oropharyngeal Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Saliva; Severity of Illness Index; Stomatitis; Taxoids; Time Factors; Tumor Necrosis Factor-alpha | 2016 |
Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prognosis; Taxoids | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Prognosis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |
Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Monitoring; Female; Humans; Injections; Luciferases, Firefly; Lung Neoplasms; Mice; Mice, Inbred BALB C; Pleural Effusion, Malignant; Taxoids; Treatment Outcome | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Inflammation; Middle Aged; Oxonic Acid; Skin Neoplasms; Taxoids; Tegafur; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Markov Chains; Pemetrexed; Quality of Life; Quality-Adjusted Life Years; Spain; Taxoids; Treatment Outcome | 2010 |
[A case of a pulmonary pleomorphic carcinoma with fever which responded well to chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids | 2010 |
Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Models, Statistical; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cell Differentiation; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Taxoids; Thyroid Neoplasms; Treatment Outcome | 2010 |
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2012 |
miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma; Cell Movement; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Genes, bcl-1; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Taxoids; Tumor Cells, Cultured | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Neutropenia; Oropharyngeal Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome; Vomiting | 2010 |
In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Topics: Adhesiveness; Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Mice, Nude; Mucous Membrane; Muscle, Smooth; Nanoparticles; Neoplasm Invasiveness; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Differentiation; Cell Line; Cell Separation; Cisplatin; Docetaxel; Humans; Hyaluronan Receptors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplastic Stem Cells; Taxoids | 2011 |
Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Membrane Glycoproteins; Membrane Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Survival Rate; Sweden; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cytochrome P-450 CYP3A; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; MicroRNAs; Neoplasms, Squamous Cell; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma.
Topics: Carcinoma; Cell Line, Transformed; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Inhibitor of Apoptosis Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Survivin; Taxoids | 2011 |
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nomograms; Prognosis; Taxoids; Treatment Outcome; Young Adult | 2011 |
mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Poly-ADP-Ribose Binding Proteins; Protein Inhibitors of Activated STAT; Retrospective Studies; RNA, Messenger; Small Ubiquitin-Related Modifier Proteins; Stomach Neoplasms; Taxoids | 2011 |
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma; Cell Survival; Crk-Associated Substrate Protein; Disease-Free Survival; Docetaxel; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Gene Silencing; Green Fluorescent Proteins; Humans; Immunoblotting; Immunohistochemistry; Kaplan-Meier Estimate; Membrane Proteins; Mice; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Phosphatidylcholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Taxoids; Transfection; Transplantation, Heterologous; Up-Regulation | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
A case of mediastinal lymph node carcinoma of unknown primary site treated with docetaxel and cisplatin with concurrent thoracic radiation therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Humans; Lymph Nodes; Male; Mediastinal Neoplasms; Mediastinum; Neoplasms, Unknown Primary; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Male; Methotrexate; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2012 |
Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2013 |
Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy Dosage; Retrospective Studies; Taxoids; Young Adult | 2012 |
Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Humans; Imatinib Mesylate; NF-kappa B; Piperazines; Pyrimidines; Taxoids; Thyroid Neoplasms | 2012 |
Lung metastases of epithelial-myoepithelial carcinoma of the parotid gland successfully treated with chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Male; Neoplasm Staging; Parotid Neoplasms; Taxoids | 2013 |
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
Topics: Animals; Carcinoma; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Nanoparticles; Ovarian Neoplasms; Particle Size; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Endoscopy; Feasibility Studies; Female; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Pharyngeal Neoplasms; Positron-Emission Tomography; Remission Induction; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Tissue Distribution | 2003 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
Progress in the management of gynecologic cancer: consensus summary statement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma; Combined Modality Therapy; Docetaxel; Drugs, Investigational; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Infusions, Parenteral; Injections, Intraperitoneal; Mass Screening; Organoplatinum Compounds; Ovarian Neoplasms; Predictive Value of Tests; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome; Uracil | 2003 |
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Neoplasms, Unknown Primary; Prognosis; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Isoflavones; Ovarian Neoplasms; Proteins; RNA Interference; Taxoids; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Zinc Fingers | 2004 |
The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma; Docetaxel; Fatal Outcome; Female; Humans; Meningitis; Middle Aged; Ovarian Neoplasms; Recurrence; Taxoids | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Docetaxel; Drug Carriers; Esophageal Neoplasms; Feasibility Studies; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Polymerase Chain Reaction; Stomach Neoplasms; Taxoids; Telomerase; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2006 |
Docetaxel administered during pregnancy for inflammatory breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fetal Development; Fluorouracil; Humans; Inflammation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids | 2006 |
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Taxoids; Treatment Outcome | 2006 |
Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Diploidy; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Taxoids; Tumor Cells, Cultured | 2007 |
[Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Anaplastic thyroid carcinoma with long term survival after combined treatment: case report.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Humans; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Thyroid Neoplasms; Treatment Outcome | 2007 |
The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; DNA Primers; Docetaxel; Female; Genes, bcl-2; Humans; In Situ Nick-End Labeling; Nitrobenzenes; Ovarian Neoplasms; RNA, Messenger; RNA, Neoplasm; Sulfonamides; Taxoids | 2007 |
Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Medical Records; Middle Aged; Multivariate Analysis; Platinum Compounds; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2007 |
In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Topics: Carcinoma; Cell Death; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Docetaxel; Female; Humans; Leukemia P388; Male; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cyclophosphamide; Cystadenocarcinoma, Papillary; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell Division; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Fluorouracil; Gene Expression; Humans; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Telomerase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Colony-Forming Units Assay; Docetaxel; Female; Humans; Linear Models; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Matched-Pair Analysis; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured | 2001 |
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |